Fenofibrate News and Research

RSS
Fenofibrate is a drug used to treat high levels of cholesterol and triglycerides in the blood. Fenofibrate is being studied in the treatment of advanced cancers in young patients and in the treatment of other conditions. It is a type of antilipidemic agent. Also called Lofibra and TriCor.
Simple trick supercharges T cells to fight stubborn solid tumors

Simple trick supercharges T cells to fight stubborn solid tumors

Does fenofibrate improve clinical outcomes in patients with COVID-19?

Does fenofibrate improve clinical outcomes in patients with COVID-19?

Study: Fenofibrate not a useful strategy for decreasing COVID-19 severity

Study: Fenofibrate not a useful strategy for decreasing COVID-19 severity

Novel drug lowers triglycerides, does not reduce cardiovascular events

Novel drug lowers triglycerides, does not reduce cardiovascular events

FDA-approved drug encourages sensory neurons to regrow after injury

FDA-approved drug encourages sensory neurons to regrow after injury

Lipid-lowering drug TriCor dramatically cuts treatment time for severe COVID-19 patients

Lipid-lowering drug TriCor dramatically cuts treatment time for severe COVID-19 patients

Eldelumab and Fenofibrate show potential for COVID-19

Eldelumab and Fenofibrate show potential for COVID-19

Chemical engineers devise a simpler process to incorporate hydrophobic drugs into tablets

Chemical engineers devise a simpler process to incorporate hydrophobic drugs into tablets

Could fenofibrate be an effective antiviral against SARS-CoV-2?

Could fenofibrate be an effective antiviral against SARS-CoV-2?

Early clinical data demonstrates the efficacy of existing drug in treating COVID-19

Early clinical data demonstrates the efficacy of existing drug in treating COVID-19

Intensive interventions in type 2 diabetes reduce risk of cardiovascular autonomic neuropathy

Intensive interventions in type 2 diabetes reduce risk of cardiovascular autonomic neuropathy

NTU-incubated start-up plans clinical trial of new slow-release pill for Parkinson’s disease

NTU-incubated start-up plans clinical trial of new slow-release pill for Parkinson’s disease

Cholesterol-lowering drugs show promise to lower COVID-19's threat

Cholesterol-lowering drugs show promise to lower COVID-19's threat

LMRI scientists discover cause of debilitating eye disease

LMRI scientists discover cause of debilitating eye disease

First genetic cause for a rare eye disease discovered

First genetic cause for a rare eye disease discovered

TSRI chemists invent new method that simplifies late-stage modification of drug molecules

TSRI chemists invent new method that simplifies late-stage modification of drug molecules

Fenofibrate drug may reduce risk of cardiovascular events in patients with type 2 diabetes

Fenofibrate drug may reduce risk of cardiovascular events in patients with type 2 diabetes

ACCORDION study shows lowering blood glucose can reduce progression of diabetic retinopathy

ACCORDION study shows lowering blood glucose can reduce progression of diabetic retinopathy

Combining 2-DG with fenofibrate could provide non-toxic treatments for many cancers

Combining 2-DG with fenofibrate could provide non-toxic treatments for many cancers

Fenofibrate benefits in diabetic retinopathy mediated through PPARα

Fenofibrate benefits in diabetic retinopathy mediated through PPARα

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.